ATAI Life Sciences NV's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.26.
During the past 3 years, the average EBIT per Share Growth Rate was -8.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ATAI Life Sciences NV's EBIT per Share or its related term are showing as below:
ATAI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -158 Med: -83.35 Max: -8.7
Current: -8.7
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of ATAI Life Sciences NV was -8.70% per year. The lowest was -158.00% per year. And the median was -83.35% per year.
ATAI's 3-Year EBIT Growth Rate is ranked worse than 64.83% of 1308
companies
in the Biotechnology industry
Industry Median: 3.5
vs ATAI: -8.70
ATAI Life Sciences NV EBIT per Share Historical Data
The historical data trend for ATAI Life Sciences NV's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV (NAS:ATAI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ATAI Life Sciences NV EBIT per Share Related Terms
Thank you for viewing the detailed overview of ATAI Life Sciences NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATAI has been successfully added to your 